## Journal of Visualized Experiments

# Assessment of oxidative damage in the primary mouse ocular surface cells/ stem cells, in response to, Ultraviolet C (UV-C) damage --Manuscript Draft--

Article Type:	Invited Methods Collection - Author Produced Video	
Manuscript Number:	JoVE59924R4	
Full Title:	Assessment of oxidative damage in the primary mouse ocular surface cells/ stem cells, in response to, Ultraviolet C (UV-C) damage	
Section/Category:	JoVE Biology	
Keywords:	UV-C, primary ocular stem cells, Reactive oxygen species (ROS), 2', 7' dichlorofluoresceindiacetate (DCFDA), "Live versus Dead cells detection in live cell cultures"	
Corresponding Author:  Bipasha Bose, PhD  Yenepoya Research Centre  Mangaluru, Karnataka INDIA		
Corresponding Author's Institution: Yenepoya Research Centre		
Corresponding Author E-Mail:	bipasha.bose@yenepoya.edu.in;Bipasha.bose@gmail.com	
Order of Authors:	Bipasha Bose, PhD	
	Saketh Kapoor	
	Utsav Sen	
	Muhammad Nihad	
	Debajit Chaudhury	
	Sudheer Shenoy P	
Additional Information:		
Question	Response	
Please indicate whether this article will be Standard Access or Open Access.		

Mangalore Sep 23, 2019

From:

Dr Bipasha Bose, PhD Associate Professor and In-charge Stem Cells and Regenerative Medicine Centre Yenepoya Research Centre Yenepoya (Deemed to be University) Mangalore-575018, Karnataka, India

To,

Dr Phillip Steindel, PhD Review Editor Journal of Visualized Experiments (JOVE)

Subject: Submission of the revised manuscript JoVE59924 - [EMID: 8f513a08842ce83b]-Revision 3

Dear Dr Phillip Steindel,

## Greetings!

I thank you for having given us the opportunity to revise the JOVE manuscript and providing us with sufficient deadline extensions. Now, we have revised the manuscript, as per the reviewer's suggestions. Please find our point-wise justifications, as well as, rebuttal towards the "Editorial Production Comments" and "Reviewer's comments".

## **Response to Editorial Production Comments**

gg

Sr	<b>Editorial Production Comments</b>	Our responses
No		
1	0:01, 0:07, 0:10-1:35, 3:42, 4:54, 5:48, 7:35, 7:39-9:12, 12:43-end - There are still black borders on the left and right sides of the frame at these points. Some are very slight. Others are very visible. In either case, the white background at these points should be extended to fill in these black borders and create a unified background. This is the third time we are mentioning this issue; the next submission needs to demonstrate that you can address this comment.	We are genuinely apologetic for being unable to understand the black border issue. However, we have now tried resolving it, and no black border is visible in our system. Please let us know, if the black border is still visible at your end and the solution for the same.

2	3:45-4:49 - The narration audio still needs to be rerecorded. The loudness of the recording is causing audio distortion.	The clip has now been re-recorded.
3	11:58-12:40 - The introductory interview statement is now synchronized. However, the conclusion statement is not. The audio appears to be a few frames ahead of the video. This needs to be corrected, or the interview needs to be rerecorded.	Thank you for the suggestion. We have now corrected the same. We have also replayed the video several times and observed that the audio and video are in sync.
4	Please cite Table 3 in the manuscript outside of the Table Legends section.	Done. Please see the in-text citation highlighted in green colour on Page 10/14 in the manuscript.

1 TITLE: 2 Assessment of Oxidative Damage in the Primary Mouse Ocular Surface Cells/Stem Cells in 3 Response to Ultraviolet-C (UV-C) Damage 4 5 **AUTHORS AND AFFILIATIONS:** 6 Bipasha Bose\*, Saketh Kapoor\*, Utsav Sen\*, Muhammad Nihad AS, Debajit Chaudhury, Sudheer 7 Shenov P 8 9 Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangaluru, Karnataka, India 10 11 12 \*Equal contribution 13 14 **Corresponding author:** 15 Dr. Bipasha Bose (Bipasha.bose@yenepoya.edu.in, Bipasha.bose@gmail.com) 16 17 **Email Addresses of Co-authors:** 18 Saketh Kapoor (sakethk@yenepoya.edu.in) 19 Utsav Sen (utsavsen@yenepoya.edu.in) 20 Muhammad Nihad AS (utsavsen@yenepoya.edu.in)

KEYWORDS

25 UV-C; primary ocular stem cells; Reactive oxygen species (ROS); 2',7'-

Debajit Chaudhury (debajit@yenepoya.edu.in)

Sudheer Shenoy P (shenoy2000@yahoo.com)

26 dichlorofluoresceindiacetate (DCFDA); Live/dead cell detection, UV-C damage

SUMMARY:

This protocol demonstrates the simultaneous detection of reactive oxygen species (ROS), live cells, and dead cells in live primary cultures from mouse ocular surface cells. 2',7'-Dichlorofluoresceindiacetate, propidium iodide, and Hoechst staining are used to assess the ROS, dead cells, and live cells, respectively, followed by imaging and analysis.

33 34

21

22

2324

2728

29

30

31

32

35

36

37

38

39

40

41

42

43

#### **ABSTRACT:**

The ocular surface is subjected to regular wear and tear due to various environmental factors. Exposure to UV-C radiation constitutes an occupational health hazard. Here, we demonstrate the exposure of primary stem cells from the mouse ocular surface to UV-C radiation. Reactive oxygen species (ROS) formation is the readout of the extent of oxidative stress/damage. In an experimental in vitro setting, it is also essential to assess the percentage of dead cells generated due to oxidative stress. In this article, we will demonstrate the 2',7'-dichlorofluoresceindiacetate (DCFDA) staining of UV-C exposed mouse primary ocular surface stem cells and their quantification based on the fluorescent images of DCFDA staining. DCFDA staining directly corresponds to ROS generation. We also demonstrate the quantification of

dead and live cells by simultaneous staining with propidium iodide (PI) and Hoechst 3332 respectively and the percentage of DCFDA (ROS positive) and PI positive cells.

#### **INTRODUCTION:**

The ocular surface (OS) is a functional unit mainly composed of the outer layer and glandular epithelia of cornea, lachrymal gland, meibomian gland, conjunctiva, part of the eye lid margins and innervations that transduce signals<sup>1</sup>. The transparent dome shaped corneal layer focuses light onto the retina. This avascular tissue is composed of cellular components such as epithelial cells, keratocytes, and endothelial cells and acellular components such as collagen and glycosaminoglycans<sup>2</sup>. The area is drained by tears that also supply most of the nutrients. The anatomical position of the OS compels it to be in direct contact with the external environment, often exposing it to various harsh components such as bright light, microbes, dust particles and chemicals. This factor predisposes the OS to physical injuries and makes it prone to various diseases.

Oxidative stress is caused due to the disequilibrium between the production of reactive oxygen species (ROS) and the endogenous antioxidant defenses mechanisms<sup>3</sup>. ROS are classified into reactive molecules and free radicals, both of which are derived from molecular oxygen ( $O_2$ ) through mitochondrial oxidative phosphorylation<sup>4</sup>. The former group is composed of non-radical species such as hydrogen peroxide ( $H_2O_2$ ), singlet oxygen ( $^1O_2$ ) and the latter includes species such as superoxide anions ( $O_2^-$ ), and hydroxyl radicals ( $^{\bullet}OH$ ), among others. These molecules are by-products of normal cellular processes and their roles have been implicated in important physiological functions such as signal transduction, gene expression, and host defense<sup>5</sup>. An enhanced production of ROS is known to be generated in response to factors such as pathogen invasion, xenobiotics, and exposure to ultra violet (UV) radiation<sup>4</sup>. This overproduction of ROS results in oxidative stress that leads to the damage of molecules such as nucleic acids, proteins, and lipids<sup>6</sup>.

Natural sunlight, the most predominant source of UV radiation, is composed of UV-A (400–320 nm), UV-B (320–290 nm), and UV-C (290–200 nm)<sup>7</sup>. An inverse correlation between the wavelength and spectral energies has been reported. Although natural UV-C radiations are absorbed by the atmosphere, artificial sources such as mercury lamps and welding instruments emit and, therefore, constitute an occupational hazard. Symptoms of exposure to eyes include photokeratitis and photokeratoconjunctivitis<sup>8</sup>. Production of ROS is one of the major mechanisms of inflicting UV induced cellular damage<sup>9</sup>. In the current study, we demonstrate the detection of ROS using the 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) staining method in mouse primary ocular surface cells/stem cells exposed to UV-C. The green fluorescence was captured using fluorescent microscopy. Cells were counter-stained with two dyes, Hoechst 33342 and red propidium iodide, to stain the live and dead cells, respectively.

#### PROTOCOL:

The experiment was performed on primary ocular cells/stem cells derived from the Swiss albino mouse eye. The use of animals for harvesting the eyes for this experiment was approved by the

Institutional Animal Ethical Committee, Yenepoya (Deemed to be University) (IEAC approval number, 6a/19.10.2016).

899091

88

#### 1. Preparations of reagents

92 93

94

95

96

NOTE: The derivation of primary cells/stem cells from the mouse ocular surface is beyond the scope of this protocol. Hence, we demonstrate the UV-C exposure doses, reagent preparation for assessing ROS, live and dead cells and their quantification. Please refer to **Table 1** for the respective volumes of the reagents (10% fetal bovine serum, DCFDA, Hoechst and propidium iodide stock solutions to be added for obtaining the final staining solution).

97 98

1.1. Prepare a stock solution of 10 mM DCFDA by dissolving 25 mg of DCFDA powder in 5.13 mL of DMSO. Aliquot 250  $\mu$ L each in amber colored 1.5 mL tubes and store at -20 °C.

101

1.2. Prepare a stock solution of 10 mg/mL (16.23 mM solution) Hoechst 33342 by dissolving the entire contents of the 25 mg vial in 2.5 mL of deionized water. Make aliquots of 100  $\mu$ L in amber colored microcentrifuge tubes and store at 2-6 °C for up to 6 months. For longer term storage, store at -20 °C.

106

1.3. Prepare a stock solution of 1 mg/mL propidium iodide in deionized water, aliquot 1 mL each in amber colored 1.5 mL tubes, and store at 4 °C.

109110

2. Cell plating and UV-C radiation treatment

111

2.1. Before plating, dissociate the mouse primary ocular surface cells isolated in our laboratory (unpublished results; such cells are a mixture of corneal epithelial, stromal cells and keratocytes) using a gentle cell dissociation agent (**Table of Materials**).

115

2.2. Plate  $0.2 \times 10^6$  mouse primary ocular surface cells in 35 mm 0.2% basement membrane matrix coated cell culture dishes in 2.5 mL of complete media. Incubate overnight at 37 °C in a 5%  $CO_2$  and humidified incubator.

119

NOTE: Complete media for culturing primary cells from the mouse ocular surface is comprised of DMEM high glucose containing 20% FBS, 1% Pen-strep, 1% Glutamax, 1% non-essential amino acid (NEAA), 1% sodium pyruvate, and 0.1%  $\beta$ -mercaptoethanol.

123

2.3. Before exposing the cells to various doses of UV-C, discard the maximum volume of media and allow only a thin layer of media ( $^{\sim}500~\mu$ L) to remain in contact with the cells, just enough to cover them.

- 2.4. Take the dishes, one at a time to the UV-C source/chamber (the lower chamber of a hybridization oven/UV cross linker; **Table of Materials**). Place the dish into the chamber and remove the lid of the dish. The open lid position of the dish ensures that the cells receive the
- maximum UV-C dose during the UV-C exposure.

1	$\sim$	$\sim$
1	•	•

2.5. Expose the cells to different grades/doses of UV-C: 1 J/m<sup>2</sup>, 100J/m<sup>2</sup>, 1,000 J/m<sup>2</sup> and 10,000  $J/m^2$ .

135

2.6. After the UV-C exposure, replace the lid of each of the dishes immediately and remove them from the UV-C source chamber.

138

2.7. Bring each of the dishes to the laminar air flow hood and top up each of the dishes with 2 mL of fresh complete media.

141

2.8. Incubate the cells for 3 h in a 37 °C CO<sub>2</sub> incubator. Three hours of incubation post UV-C exposure is optimal to visualize and quantify the early effects.

144

## 3. Preparation of live-cell staining media

145146

3.1. Prepare the staining media fresh during the last 15 min of the 3 h cell incubation post UV-C exposure.

149

3.2. Pre-warm 10 mL of the staining media containing 10% FBS-DMEM supplemented with 1% Pen-Strep to 37 °C.

152

3.3. Add 5  $\mu$ L of 10 mM DCFDA; 5  $\mu$ L of 10 mg/mL Hoechst solution and 200  $\mu$ L of 1 mg/mL propidium iodide. The final concentrations of DCFDA, Hoechst and PI are 5  $\mu$ M, 5  $\mu$ g/mL and 20  $\mu$ g/mL, respectively, in the 10 mL of staining media.

156

## 4. DCFDA staining of UV-C exposed mouse primary ocular cells

157158159

4.1. After 3 h of incubation of UV-C exposed mouse primary ocular cells at various doses, aspirate the media from the 35 mm dishes.

160161

4.2. Replenish with 2 mL of freshly prepared DCFDA staining media to each of the dishes gentlyfrom the sides.

164

4.3. Incubate the cells with the staining media for 15 min in the dark in a 37 °C CO<sub>2</sub> incubator for live-cell staining.

167

## 168 5. Viewing of DCFDA (ROS), Hoechst and PI stained cells

169

170 5.1. After the completion of incubation, discard the staining media.

171

5.2. Add fresh complete media to the cells and observe the cells under an inverted fluorescent microscope/cell imager (**Table of Materials**). Photograph the desired fields: bright-field, blue fluorescence, red fluorescence, green fluorescence.

NOTE: The blue fluorescently stained cells are the nuclei, the green fluorescence is for ROS generating cells and the red fluorescence indicates the PI positive dead cells.

6. Quantification of stained cells (Hoechst-Blue, PI-Dead and Green-ROS) using imaging techniques

6.1. Export the images captured under the inverted fluorescent microscope/cell imager to ImageJ for quantification.

6.2. Open each of the images one at a time, using each channel (i.e., blue (Nuclei/Hoechst), green (ROS), red (Dead/PI positive)) sequentially, for counting. Start from the unexposed control and sequentially move to 1, 100, 1,000 and 10,000 J/m<sup>-2</sup>.

6.3. Count the cells using the cell counting tool marked as a cross in the software menu for each of the fields [blue positive (Hoechst positive; nuclei), red positive (PI positive; dead cells); green positive (ROS)] in each of the images corresponding to each of the treatments.

6.4. Count by clicking on each of the specific signals in each of the fields. For example, clicking on the blue/Hoechst stained nuclei will give the total number of nuclei in a given field.

6.5. Calculate the results as the **percentage of cell death by UV damage** (number of PI positive cells x 100 divided by the number of Hoechst positive cells) and the **percentage of ROS production by UV damage** (number of DCFDA positive cells x 100 divided by the number of Hoechst positive cells).

#### **REPRESENTATIVE RESULTS**

DCFDA is a colorless dye that is a chemically reduced form of fluorescein used as an indicator for detecting ROS in cells. This dye gets trapped inside cells and is easily oxidized to fluorescent dichlorodihydrofluorescein (DCF), which emits a green fluorescence. This fluorescence can be detected using fluorescent microscopy. The cells can be visualized and correlated with ROS accumulation as follows: (i) live cells without ROS emit high blue fluorescence; (ii) live cells with ROS accumulation emit high blue fluorescence with low green fluorescence; and (iii) dead cells with ROS accumulation emit low blue fluorescence with high red and high green fluorescence.

Control cells and cells exposed to 1 J/m<sup>2</sup> of UV-C did not exhibit DCFDA/ROS and PI positive cells. The UV-C unexposed control showed nuclear staining only as indicated by the Hoechst staining (**Figure 1**). However, no PI or DCFDA positive cells were seen in the UV-C unexposed control cells (**Figure 1**).

Cells exposed to 100 J/m<sup>2</sup> of UV-C exhibited low ROS and PI positive cells. Primary cells from the mouse ocular surface upon exposure to UV-C at a dose of 100 J/m<sup>2</sup> showed about 5% costaining of DCFDA and PI, thereby, indicating the formation of ROS and cell death in 5% of the cells (**Figure 1**).

Cells exposed to 1,000 J/m<sup>2</sup> of UV-C exhibited 60%–70% ROS and PI positive cells. Primary cells from mouse ocular surface upon exposure to UV-C at a dose of 1,000 J/m<sup>2</sup> showed about 70% co-staining of DCFDA and PI, thereby, indicating the formation of ROS and cell death in 70% of the cells (**Figure 1**).

Cells exposed to  $10,000 \text{ J/m}^2$  of UV-C exhibited 100% ROS positive cells and ~100% cell death. The highest UV-C dose ( $10,000 \text{ J/m}^2$ ) when exposed to the mouse ocular primary cells resulted in 100% cell death (PI positive cells) and ROS formation (DCFDA staining), thereby indicating the highest lethality of this particular UV-C dose (**Figure 1**).

Cells treated with 1 J/m² of UV-C radiation did not show any accumulation of ROS and the percentage of live cells in this dose was comparable with that of the control cells. Cells demonstrated a significant amount of cell death and ROS accumulation at 100 J/m². The highest amount of ROS accumulation and cell death was observed in cells treated with 10,000 J/m² of UV-C radiation.

The quantified results (percentage of ROS generation and percentage of cell death as per the formulae given under section 6.3) were plotted in the form of a bar graph (**Figure 2**). The X-axis represents the UV-C doses while the Y-axis represents the percentage of cells. The green bar represents the percentage of ROS, and the red bars represent the cell death at different doses of UV-C radiation (**Figure 2**). The percentage of ROS and dead cells were of the order of 0%, 0%, 10%, 70% and 100% at the UV-C doses: unexposed control, 1 J/m², 100 J/m², 1,000 J/m² and 10,000 J/m², respectively (**Figure 2**).

#### FIGURE AND TABLE LEGENDS:

Figure 1: Composite live-cell images of the mouse ocular surface primary cells exposed to various doses of UV-C (Unexposed control, 1, 100, 1,000, 10,000 J/m²). These images were captured under different filters: bright-field (for cell morphology), blue (Hoechst nuclear stain), green (ROS generation) and red (propidium iodide stained dead cells).

Figure 2: Bar graphs showing the quantification results obtained after calculating the percentage of ROS generation and percentage of dead cells upon exposure of primary mouse ocular surface cells to various doses of UV-C radiation. The X-axis represents the UV-C doses, while the Y-axis represents the percentage of cells.

Table 1: Reagents required for the preparation of staining solution.

**Table 2: Troubleshooting.** 

#### **DISCUSSION:**

The DCFDA staining method described here enables the visualization of ROS in mouse primary ocular live cells treated with UV-C radiation. An advantage of this staining method is that it also allows the researchers to study the immediate effects of UV-C (3 hours post UVC exposure) on the live cells and their simultaneous enumeration for the percentage of ROS positive, as well as,

dead cells. Moreover, as the staining method is used on the live cells, the cells can be further incubated in the same media for a longer time (several days) for the study of delayed effects of UV-C radiation. Hence, this staining method makes it possible to visualize the ROS generation (green) and simultaneously distinguish the live, apoptotic and dead cell populations in live cells under an inverted fluorescence microscope. However, under certain circumstances, despite the anticipation of obtaining ROS positive and PI positive cells, the visualization can fail. For such instances, troubleshooting is suggested (**Table 2**).

This protocol must be carried out accurately to obtain optimal results. Optimal results indicate a correlation of the green fluorescent signal emitted/ROS generated as an accurate readout of the specific UV-C dose induced DNA damage. In other words, for carrying out this step, the volume of media that is in contact with the cells during the UV-C exposure should not be so much so that the UV-C dose fails to elicit the required damage. Hence, it is essential to keep a minimal volume of media, say 500  $\mu L$  per 35 mm dish, just enough to cover the cells during the UV-C exposure at all the specified doses. Secondly, the volume of media should not be so little that the cells dry up during UV-C exposure. Finally, immediately after the exposure of the cells to the UV-C, the cells should be topped up with fresh media to the optimal volume (say 2 mL),

in order to further avoid any damages and ROS generation.

One limitation of this technique is the type of ROS generated. Other additional assays must be performed to detect the specific ROS type in response to the UV-C dose ranges. Such assays include the assessment of the intracellular hydroxyl radical (\*OH), intracellular superoxide radicals, intracellular reactive nitrogen species, mitochondrial hydroxyl radicals, mitochondrial superoxides, and hydrogen peroxide in live cells using commercially available kits. Another limitation of this technique is the detectability of the percentage ROS generation at doses below 10 J/m² and above 10,000 J/m². Apparently, no ROS positive cells were visible when the primary cells/stem cells from the mouse ocular surface were exposed to UV-C doses less than 10 J/m². On the contrary, 100% ROS positive cells were visible when the cells were exposed to UV-C dose above 10,000 J/m². Hence, other assays (e.g., enzyme analysis, measurement of oxidative stress markers such as 8-hydroxydeoxyguanosine (8-OHdG) (DNA damage marker), and western blot analysis of DNA damage proteins at various doses) might be useful to understand the extent/type of cellular/molecular damages at various levels. A third limitation of this technique is the correlation of the UV-C doses to the ROS generated across various cell types. This needs to be validated.

Currently, DCFDA kits are available commercially for ROS detection either using microscopy or flow cytometry<sup>10,11</sup>. However, such kits are expensive and cannot be afforded by research laboratories in resource restricted countries. Hence, this protocol is very useful with an efficiency akin to the commercially sold methods. Secondly, we have incorporated the propidium iodide dead cell stain along with the DCFDA/ROS generation. Hence, live cell monitoring of ROS positive and dead cells can be carried out simultaneously using this method.

#### **AKNOWLEDGMENTS:**

The authors acknowledge support from the Yenepoya Research Centre, Yenepoya (Deemed to be University) for the infrastructural facilities.

309 310

#### DISCLOSURES:


Authors received funding support from Bio-Rad Laboratories India Private Limited for sponsoring the article.


313314

#### **REFERENCES:**

- Gipson, I. K. The ocular surface: the challenge to enable and protect vision: the Friedenwald lecture. *Investigative Ophthalmology and Visual Science.* **48** (10), 4390; 4391-4398 (2007).
- Sridhar, M. S. Anatomy of cornea and ocular surface. *Indian Journal of Ophthalmoogy.* **66** (2), 190-194 (2018).
- 320 3 Betteridge, D. J. What is oxidative stress? *Metabolism.* **49** (2 Suppl 1), 3-8 (2000).
- Ray, P. D., Huang, B. W., Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signaling*. **24** (5), 981-990 (2012).
- Nita, M., Grzybowski, A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. *Oxidative Medicine and Cellular Longevity.* **2016**, 3164734 (2016).
- Covarrubias, L., Hernandez-Garcia, D., Schnabel, D., Salas-Vidal, E., Castro-Obregon, S. Function of reactive oxygen species during animal development: passive or active?

  Developmental Biology. **320** (1), 1-11 (2008).
- Behar-Cohen, F. et al. Ultraviolet damage to the eye revisited: eye-sun protection factor (E-SPF(R)), a new ultraviolet protection label for eyewear. *Clinical Ophthalmology.* **8**, 87-104 (2014).
- 333 8 Izadi, M., Jonaidi-Jafari, N., Pourazizi, M., Alemzadeh-Ansari, M. H., Hoseinpourfard, M. J. Photokeratitis induced by ultraviolet radiation in travelers: A major health problem. 335 *Journal of Postgraduate Medicine.* **64** (1), 40-46 (2018).
- de Jager, T. L., Cockrell, A. E., Du Plessis, S. S. Ultraviolet Light Induced Generation of
   Reactive Oxygen Species. Advances in Experimental Medicine and Biology. 996, 15-23
   (2017).
- 339 10. Degl'Innocenti, D. et al. Oxadiazon affects the expression and activity of aldehyde dehydrogenase and acylphosphatase in human striatal precursor cells: A possible role in neurotoxicity. *Toxicology.* **411**, 110-121 (2019).
- 342 11. Li, Z. et al. APC-Cdh1 Regulates Neuronal Apoptosis Through Modulating Glycolysis and 343 Pentose-Phosphate Pathway After Oxygen-Glucose Deprivation and 344 Reperfusion. *Cellular and Molecular Neurobiology.* **39**, 123-135 (2019).





Component	Volume
10% Fetal Bovine Serum containing DMEM	9790 μL
DCFDA stock solution	5 μL
Hoechst 33342 stock solution	5 μL
Propidium iodide stock solution	200 μL

Problem	Probable reasons
No or very little ROS or PI positive cells are	i. Use of an old staining
stained when the cells were treated with high to	solution.
highest UV dose	ii. Overconfluent culture dish
	resulting in salvage of UVC
	damage by the cells.

Troubleshooting	Comments	
i. Use freshly prepared staining	i. Earlier prepared staining solution leads to	
solution.	improper staining of the cells.	
ii. Plate only 0.2 million cells in	ii. Overconfluent cells can salvage of UVC damage,	
each 35 mm cell culture dish and and hence no or little ROS and PI positive cells wil		
never allow the cells to grow for be visualized.		
more than 12 h before exposing		
them to UVC doses.		

Name of Material/Equipment	Company	<b>Catalog Number</b>
2', 7' –dichlorofluorescein diacetate(DCFDA)	Sigma	D6883
Cell culture dish (35 mm)	Eppendorf	SA 003700112
DMEM High Glucose	HiMedia	AT007
		RM99955
Fetal Bovine Serum, EU Origin	HiMedia	
GlutMax	Gibco, Thermo Fisher Scientific	35050061
HL-2000 Hybrilinker	UVP	
Hoechst 33342	Sigma	B2261
Matrigel	Sigma Corning	
MEM Non-Essential Amino Acids (100X)	Gibco, Thermo Fisher Scientific	11140050
Penicillin-Streptomycin (Pen-Strep)	Gibco, Thermo Fisher Scientific	15140122
remaini-sueptomyan (ren-suep)	dibco, memio risnei scientino	13140122
Propidium Iodide	Sigma	P4170
TryplE Express	Thermo Fisher Scientific	
ZOE Fluorescent Cell Imager	Bio-rad	
202 man essent sen mager	2.0 .00	

#### **Comments/Description**

2',7'-Dichlorofluorescein diacetate is fluorogenic probe and is permeable to cells. It is used for quantification of reactive oxygen species.

Sterile dishes for culturing the cells.

Most widely used cell culture media, contains 4500 mg/L of glucose.

One of the most important components of cell culture media. It provides growth factors, amino acids, proteins, fat-soluble vitamins such as A, D, E, and K, carbohydrates, lipids, hormones, minerals, and trace elements.

Used as a supplement and an alternative to L-glutamine. It helps in improving cell viability and growth.

Hybridization oven/UV cross linker

Hoechst stain is permeable to both live and dead cells. It binds to double starnded DNA irrespective of wether the cell is dead or alive.

Basement membrane matrix

Used as a supplement to increase the cell growth and viability.

Penicillin and streptomycin is used to prevent the bacterial contamination in culture.

Fluorescent dye which is only permeable to dead cells. It binds with DNA and helps in distinguishing between live and dead cells.

Gentle cell dissociation agent



## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:	Assessment of oxidative damage in the primary mouse ocular				
Author(s):	Assessment of oxidative damage in the primary mouse ocular surface cus stem cells, in response to, Ultraviolet e Cuv-e) damage Paipasha Bose, Saketh Kapoor, Utsav Sen, Muhammad Nihad AS, Debajit Chaudhury, Sadhur Author elects to have the Materials be made available (as described at Shenoy Peccom/publish) via:				
Item 1: The Author elects to have the Materials be made available (as described at Shenoy Phttp://www.jove.com/publish) via:					
	elect one of the following items: nor is <b>NOT</b> a United States government employee.				
The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.  The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.					

## ARTICLE AND VIDEO LICENSE AGREEMENT

Defined Terms. As used in this Article and Video License Agreement, the following terms shall have the following meanings: "Agreement" means this Article and Video License Agreement; "Article" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "Author" means the author who is a signatory to this Agreement; "Collective Work" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "CRC License" means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: http://creativecommons.org/licenses/by-nc-

nd/3.0/legalcode; "Derivative Work" means a work based upon the Materials or upon the Materials and other preexisting works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment. condensation, or any other form in which the Materials may be recast, transformed, or adapted; "Institution" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "JoVE" means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "Materials" means the Article and / or the Video; "Parties" means the Author and JoVE; "Video" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

- 2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.
- Grant of Rights in Article. In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to Sections 4 and 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in Item 1 above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

- 4. Retention of Rights in Article. Notwithstanding the exclusive license granted to JoVE in Section 3 above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.
- 5. Grant of Rights in Video Standard Access. This Section 5 applies if the "Standard Access" box has been checked in Item 1 above or if no box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to Section 7 below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.
- Grant of Rights in Video Open Access. This Section 6 applies only if the "Open Access" box has been checked in Item 1 above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to Section 7 below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.
- 7. Government Employees. If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in Item 2 above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

- rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.
- 8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.
- 9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.
- Author Warranties. The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.
- 11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole



## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

Indemnification. The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to

the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

- 13. Fees. To cover the cost incurred for publication, JoVE must receive payment before production and publication of the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.
- 14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

## CORRESPONDING AUTHOR

Name:	
	DR. BIPASHA BOSE
Department:	STEM CELLS AND REGENERATIVE MEDICINE CENTRE
Institution:	YENEPOYA RESEARCH CENTRE. YENEPOYA (DEFOICE TORE UNIVERSITY)
Title:	Assessment of Oxidative damage in the primary mouse ourlar surface cells stem cells, in response to, Ultraviolet C Cur-gradiation
Signature:	Bigashi Bose Date: Feb 28, 2019

Please submit a signed and dated copy of this license by one of the following three methods:

- 1. Upload an electronic version on the JoVE submission site
- 2. Fax the document to +1.866.381.2236
- 3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

Mangalore Sep 23, 2019

From:

Dr Bipasha Bose, PhD Associate Professor and In-charge Stem Cells and Regenerative Medicine Centre Yenepoya Research Centre Yenepoya (Deemed to be University) Mangalore-575018, Karnataka, India

To, Dr Phillip Steindel, PhD Review Editor Journal of Visualized Experiments (JOVE)

Subject: Rebuttal letter for the submission of the revised manuscript JoVE59924 - [EMID: 8f513a08842ce83b]-Revision 3

Dear Dr Phillip Steindel,

Greetings!

I thank you for having given us the opportunity to revise the JOVE manuscript and providing us with sufficient deadline extensions. Now, we have revised the manuscript, as per the reviewer's suggestions. Please find our point-wise justifications, as well as, rebuttal towards the "Editorial Production Comments" and "Reviewer's comments".

#### **Response to Editorial Production Comments**

gg


Sr	<b>Editorial Production Comments</b>	Our responses
No		
1	0:01, 0:07, 0:10-1:35, 3:42, 4:54, 5:48, 7:35, 7:39-9:12, 12:43-end - There are still black borders on the left and right sides of the frame at these points. Some are very slight. Others are very visible. In either case, the white background at these points should be extended to fill in these black borders and create a unified background. This is the third time we are mentioning this issue; the next submission needs to demonstrate that you can address this comment.	We are genuinely apologetic for being unable to understand the black border issue. However, we have now tried resolving it, and no black border is visible in our system. Please let us know, if the black border is still visible at your end and the solution for the same.

2	3:45-4:49 - The narration audio still needs to be rerecorded. The loudness of the recording is causing audio distortion.	The clip has now been re-recorded.
3	11:58-12:40 - The introductory interview statement is now synchronized. However, the conclusion statement is not. The audio appears to be a few frames ahead of the video. This needs to be corrected, or the interview needs to be rerecorded.	Thank you for the suggestion. We have now corrected the same. We have also replayed the video several times and observed that the audio and video are in sync.
4	Please cite Table 3 in the manuscript outside of the Table Legends section.	Done. Please see the in-text citation highlighted in green colour on Page 10/14 in the manuscript.


## ImageJ steps



Step 6.2: Blue channel images



Step 6.3: Cell counting tool



Step 6.3: Clicking on the blue/Hoechst stained nuclei